Kura Oncology Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $9.78
- Today's High:
- $10.01
- Open Price:
- $9.98
- 52W Low:
- $9.28
- 52W High:
- $17.27
- Prev. Close:
- $10
- Volume:
- 466404
Company Statistics
- Market Cap.:
- $742.36 million
- Book Value:
- 6.2
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -19.19%
- Return on Equity TTM:
- -30.77%
Company Profile
Kura Oncology Inc had its IPO on 2015-09-22 under the ticker symbol KURA.
The company operates in the Healthcare sector and Biotechnology industry. Kura Oncology Inc has a staff strength of 133 employees.
Stock update
Shares of Kura Oncology Inc opened at $9.98 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $9.78 - $10.01, and closed at $9.95.
This is a -0.5% slip from the previous day's closing price.
A total volume of 466,404 shares were traded at the close of the day’s session.
In the last one week, shares of Kura Oncology Inc have slipped by -1.09%.
Kura Oncology Inc's Key Ratios
Kura Oncology Inc has a market cap of $742.36 million, indicating a price to book ratio of 2.0996 and a price to sales ratio of 0.
In the last 12-months Kura Oncology Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-147500992. The EBITDA ratio measures Kura Oncology Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Kura Oncology Inc’s operating margin was 0% while its return on assets stood at -19.19% with a return of equity of -30.77%.
In Q2, Kura Oncology Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Kura Oncology Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-2.15 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Kura Oncology Inc’s profitability.
Kura Oncology Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -3.4037. Its price to sales ratio in the trailing 12-months stood at 0.
Kura Oncology Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $-604992000.00
- Total Liabilities
- $23.90 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $96000
- Dividend Payout Ratio
- 0%
Kura Oncology Inc ended 2024 with $-604992000.00 in total assets and $0 in total liabilities. Its intangible assets were valued at $-604992000.00 while shareholder equity stood at $-640051000.00.
Kura Oncology Inc ended 2024 with $0 in deferred long-term liabilities, $23.90 million in other current liabilities, 7000.00 in common stock, $-640051000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $49.12 million and cash and short-term investments were $476.98 million. The company’s total short-term debt was $2,345,000 while long-term debt stood at $9.24 million.
Kura Oncology Inc’s total current assets stands at $476.98 million while long-term investments were $0 and short-term investments were $427.86 million. Its net receivables were $0 compared to accounts payable of $2.34 million and inventory worth $0.
In 2024, Kura Oncology Inc's operating cash flow was $0 while its capital expenditure stood at $96000.
Comparatively, Kura Oncology Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $9.95
- 52-Week High
- $17.27
- 52-Week Low
- $9.28
- Analyst Target Price
- $29.88
Kura Oncology Inc stock is currently trading at $9.95 per share. It touched a 52-week high of $17.27 and a 52-week low of $17.27. Analysts tracking the stock have a 12-month average target price of $29.88.
Its 50-day moving average was $10.41 and 200-day moving average was $11.92 The short ratio stood at 11.37 indicating a short percent outstanding of 0%.
Around 175.5% of the company’s stock are held by insiders while 10091.4% are held by institutions.
Frequently Asked Questions About Kura Oncology Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase for the treatment of solid tumors and hematologic indications. The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.